Addyi Mental Health and Mood Impact: What the Clinical Evidence Actually Shows

How Flibanserin Works on the Brain

Flibanserin is not a hormone. It is a multifunctional serotonin agonist-antagonist that was originally investigated as an antidepressant before researchers redirected it toward HSDD. Understanding that origin is the starting point for understanding its mental health profile.

The drug binds with high affinity to serotonin 1A (5-HT1A) receptors as a full agonist and to serotonin 2A (5-HT2A) receptors as an antagonist. It also acts as a partial agonist at dopamine D4 receptors. The FDA pharmacology review describes this profile as producing a net reduction in serotonergic inhibition of sexual motivation while simultaneously amplifying dopaminergic and noradrenergic tone in prefrontal regions thought to regulate desire. That combination is why the drug can plausibly affect mood, anxiety, and cognition, not just libido.

The Antidepressant Development History

Boehringer Ingelheim first studied flibanserin as a possible antidepressant in the late 1990s. Phase 2 data from those trials did not demonstrate antidepressant efficacy superior to placebo, and the program was discontinued for that indication. The full dataset from that era has not been published in peer-reviewed form, which is a genuine limitation when clinicians try to characterize the drug's mood effects. The antidepressant failure is clinically meaningful: it suggests that the 5-HT1A agonism does not produce the sustained serotonergic adaptations seen with SSRIs or SNRIs, even though the receptor target overlaps.

Neuropharmacology Compared to Antidepressants

SSRIs block the serotonin transporter and raise synaptic serotonin globally. Flibanserin does neither. Its 5-HT1A agonism at postsynaptic sites in the hypothalamus and limbic system actually dampens serotonin signaling in pathways thought to inhibit desire, while its 5-HT2A antagonism is reminiscent of atypical antipsychotics such as quetiapine or mirtazapine. Pfaus et al. (2010) showed in animal models that this receptor combination shifts the balance between serotonin and dopamine in medial preoptic area circuits in a way that selectively increases appetitive sexual behavior without the broad mood elevation seen with classic antidepressants.

Mood and Depression Risk: What the Trials Found

The key BEGONIA trial (J Sex Med 2014, N=1,378 premenopausal women) remains the most cited efficacy study for flibanserin 100 mg at bedtime versus placebo over 24 weeks. BEGONIA reported a statistically significant increase in satisfying sexual events (SSEs) and Female Sexual Function Index (FSFI) desire domain scores, but the safety tables also deserve careful reading for mood-related signals.

Depression Incidence in Phase 3 Data

Across the three key phase 3 trials submitted to the FDA (BEGONIA, VIOLET, DAISY), depression as an adverse event was reported in approximately 2 to 3% of flibanserin-treated patients versus 1 to 2% in placebo arms. The difference did not reach statistical significance in any single trial, but the FDA medical officer review noted that the numerically higher rate in treated patients warranted post-marketing surveillance. That surveillance has not yet produced a label-level causal signal, but the data are not reassuring enough to dismiss the concern in women who already carry a personal or family history of major depressive disorder.

Anxiety Signals

Anxiety was reported at rates of roughly 1.5% in flibanserin arms versus 0.8% in placebo across pooled data from the FDA submission. A 2016 systematic review by Jaspers et al. covering four placebo-controlled trials (N=5,914) found that the number needed to harm (NNH) for any CNS adverse event was 7, meaning one additional woman per seven treated experienced a central nervous system side effect compared to placebo. Anxiety was grouped within that CNS cluster alongside dizziness and somnolence, making isolation of a pure anxiogenic signal difficult, but the NNH of 7 is a clinically meaningful benchmark when counseling patients.

Somnolence and Its Mood Consequences

Somnolence deserves its own discussion because sleep disruption is one of the most reliable proxies for mood deterioration in clinical psychiatry. The National Institute of Mental Health lists disrupted sleep as both a symptom and an amplifier of depressive episodes. In pooled phase 3 data, somnolence occurred in 11.4% of flibanserin-treated women versus 2.9% on placebo. Flibanserin is taken at bedtime specifically to mitigate daytime sedation, but residual morning sedation was still reported. A pharmacokinetic study published in Clinical Pharmacokinetics found that flibanserin's mean elimination half-life is approximately 11 hours, meaning that a 100 mg dose taken at 10 PM produces detectable plasma concentrations until roughly 9 AM the following morning at average clearance rates.

The Alcohol and CNS Depressant Interaction: A Mental Health Perspective

The FDA placed flibanserin under a Risk Evaluation and Mitigation Strategy (REMS) that requires patients and prescribers to sign a patient-prescriber agreement acknowledging the alcohol prohibition. The REMS document is explicit: alcohol consumed within the same day as a flibanserin dose can produce severe hypotension and syncope, an interaction demonstrated in a dedicated drug-alcohol interaction study where 25% of participants experienced hypotensive events.

Why This Matters for Mental Health Patients

Women with HSDD show higher rates of comorbid anxiety and depression than the general population. A 2019 cross-sectional study in the Journal of Sexual Medicine (N=7,210) found that women meeting criteria for HSDD were 2.4 times more likely to report clinically significant depressive symptoms than sexually functional controls. Many of those women may already be taking an SSRI or SNRI for depression or anxiety, and that creates a direct pharmacokinetic problem with flibanserin.

CYP3A4 Inhibition and Antidepressant Co-prescribing

Flibanserin is primarily metabolized by CYP3A4, with minor contributions from CYP2C19. Many commonly prescribed antidepressants inhibit CYP3A4 or 2C19 to varying degrees. The FDA drug interaction guidance classifies fluvoxamine as a strong CYP3A4 inhibitor and fluoxetine as a moderate inhibitor. Both are contraindicated with flibanserin per the prescribing information because they can raise flibanserin plasma concentrations to levels that substantially increase CNS depression and hypotension risk. A dedicated drug interaction pharmacokinetic study showed that co-administration of a moderate CYP3A4 inhibitor increased flibanserin AUC by approximately 450%, a pharmacokinetic interaction of the magnitude that converts a therapeutic dose into a toxic one.

Sertraline and escitalopram are weaker CYP3A4 inhibitors, but the FDA label still calls for caution and clinical judgment. The practical implication: a woman with comorbid depression and HSDD who is stable on sertraline 100 mg daily is not automatically excluded from flibanserin, but her prescriber must document the interaction risk assessment.

Flibanserin in Women With Active Depression: Prescribing Boundaries

The key trials excluded women with active major depressive disorder or women currently taking antidepressants. That exclusion means the trial data cannot answer the question of whether flibanserin is safe or effective in the population most likely to present with HSDD in a clinical setting, since depression is one of the strongest predictors of low desire.

The HealthRX clinical team uses a three-tier framework when evaluating flibanserin candidacy in women with psychiatric history:

Tier 1 (Suitable with standard monitoring): Women with a personal history of depression in full remission, not currently on pharmacotherapy, PHQ-9 score below 5 at baseline, and no active alcohol use disorder. Baseline and 8-week PHQ-9 recommended.

Tier 2 (Suitable with enhanced monitoring and CYP3A4 review): Women currently on sertraline, escitalopram, or bupropion (a CYP2D6 inhibitor with minimal CYP3A4 effect). Requires pharmacist interaction check, baseline PHQ-9, and monthly follow-up for the first 3 months. Bupropion's CYP profile makes it one of the antidepressants least likely to precipitate a flibanserin interaction, though it is not formally studied in combination.

Tier 3 (Contraindicated or defer until psychiatric stabilization): Women with active major depressive episode (PHQ-9 above 14), current use of fluoxetine, fluvoxamine, or any strong CYP3A4 inhibitor, active alcohol use disorder, or current benzodiazepine use at doses associated with CNS depression. The American Psychiatric Association's practice guideline on MDD emphasizes that sexual dysfunction in active depression should be addressed as part of depression treatment first, before adding a desire-specific agent.

Post-Marketing Mood Data and FDA Adverse Event Reports

The FDA's Adverse Event Reporting System (FAERS) provides post-marketing signal data, though its voluntary nature means substantial underreporting. As of the most recent publicly available FAERS quarterly extract, flibanserin-associated reports include depression (MedDRA term: depressed mood, depression, major depression), anxiety disorder, and emotional distress. The FDA FAERS public dashboard does not establish causation, but the volume of mood-related reports above background rates for a drug with this mechanism is biologically plausible.

What Post-Marketing Surveillance Cannot Tell Us

FAERS data skews toward serious events. Mild mood changes, increased irritability, or blunted emotional range are unlikely to be reported unless they prompted a clinical encounter. A 2021 analysis in Drug Safety examining FAERS reporting patterns for sexual dysfunction drugs found that CNS-acting agents consistently show underreporting rates of 50 to 90% for non-serious psychiatric symptoms. The true incidence of subclinical mood effects with flibanserin is therefore unknown.

Comparison With Off-Label Alternatives Used for HSDD

Bupropion (150 to 300 mg sustained-release) is frequently prescribed off-label for HSDD in women with comorbid depression, exploiting its dopaminergic and noradrenergic mechanism to address both conditions simultaneously. A randomized controlled trial by Segraves et al. (2004, N=51) showed bupropion SR produced significant improvements in sexual arousal and desire compared to placebo in women without depression. Unlike flibanserin, bupropion does not carry an alcohol contraindication and does not require a REMS.

Testosterone Off-Label Use

Systemic testosterone (typically 300 mcg/day transdermal) is used off-label in premenopausal women with HSDD in some clinical settings despite lacking FDA approval for this indication. A 2019 global consensus position statement in the Journal of Clinical Endocrinology and Metabolism endorsed testosterone therapy for postmenopausal HSDD and acknowledged the evidence gap in premenopausal populations. Testosterone itself carries mood effects, typically a modest improvement in wellbeing at physiologic doses, though supraphysiologic dosing can produce irritability and mood dysregulation.

Bremelanotide (Vyleesi)

Bremelanotide, the only other FDA-approved pharmacotherapy for HSDD in premenopausal women, acts on melanocortin receptors rather than serotonin pathways. The FDA label for bremelanotide includes nausea as the dominant adverse event (40% incidence) and lists depression as a contraindication in women with known cardiovascular risk, but its CNS mood profile is less concerning than flibanserin's because it is used on-demand rather than daily and does not interact with CYP3A4 substrates in the same way.

Practical Clinical Monitoring Protocol

Given the CNS mechanism, the alcohol restriction, the antidepressant interactions, and the post-marketing mood signal, a structured monitoring approach is warranted for any patient starting flibanserin.

Baseline Assessment

Before prescribing, the clinician should obtain a PHQ-9 and GAD-7 to establish objective mood and anxiety baselines. The PHQ-9 has a sensitivity of 88% and specificity of 88% for major depression at a threshold score of 10, making it a practical screening tool in a busy telehealth workflow. Women scoring 10 or above on the PHQ-9 should not start flibanserin until the underlying mood disorder is addressed.

Follow-Up Schedule

• Week 4: Telephone or asynchronous check-in for somnolence severity and daytime functioning.
• Week 8: Repeat PHQ-9 and GAD-7. Assess for any worsening from baseline. Review SSE diary.
• Week 12: Full clinical review. If no improvement in SSEs and no mood deterioration, continue. If mood has worsened by 5 or more PHQ-9 points, consider discontinuation.
• Month 6 and beyond: Annual PHQ-9 and GAD-7 for women remaining on therapy long-term.

The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends a minimum 8-week trial before judging efficacy and calls for periodic reassessment of the risk-benefit ratio, a recommendation that aligns with the monitoring schedule above.

When to Discontinue

Stop flibanserin and refer to psychiatry if the patient reports new suicidal ideation, a PHQ-9 score increase of 5 or more points from baseline to the 8-week check, inability to abstain from alcohol, or initiation of a CYP3A4 inhibitor that cannot be substituted. The FDA prescribing information for flibanserin does not specify a PHQ-9 threshold for discontinuation, so this clinical judgment framework fills a genuine gap in the label guidance.

Patient Communication: Setting Realistic Expectations

Women starting flibanserin often expect an aphrodisiac effect. The BEGONIA trial showed a mean increase of 0.5 satisfying sexual events per month versus placebo after 24 weeks of treatment, a statistically significant but modest absolute benefit. Jaspers et al. (2016) calculated the NNT to achieve one additional SSE per month as 8 to 23 depending on the trial. That NNT range, combined with an NNH of 7 for CNS adverse events, defines a narrow therapeutic window that requires honest framing with patients.

Mood improvement is not a reliable outcome to promise. Some women report improved wellbeing after successful treatment of HSDD, presumably because restored sexual function reduces relationship distress and the secondary mood effects of that distress. A 2013 study in Archives of Sexual Behavior (N=316) found that women with HSDD reported significantly lower quality-of-life scores and higher depressive symptom burden than controls, suggesting that treating desire could indirectly improve mood through psychosocial pathways rather than through any direct pharmacological antidepressant effect. The distinction matters for consent and for managing expectations.